X4 Pharmaceuticals Appoints Experienced Biotech CFO Kelly Gold to Board
XFOR has more than doubled off its 52-week low of $1.35.
Summary
X4 Pharmaceuticals appointed Kelly Gold, an experienced biotech CFO, to its Board of Directors and Audit Committee, enhancing the company's financial and strategic oversight.
Key Events · Executive and Board Changes · XFOR
-
New Director Appointment
Kelly Gold was appointed as a Class II director, effective July 1, 2026, increasing the board size from five to six members.
-
Strengthened Financial Expertise
Ms. Gold, currently CFO of CAMP4 Therapeutics, brings significant financial leadership, capital markets, and strategic planning experience from her roles at CAMP4, Biogen, and Deutsche Bank.
-
Audit Committee Role
Ms. Gold will also serve on the Audit Committee, enhancing financial oversight for the company.
Analysis · XFOR · Life Sciences
X4 Pharmaceuticals has strengthened its board by appointing Kelly Gold, a seasoned Chief Financial Officer from another public biopharmaceutical company, to its Board of Directors and Audit Committee. Her extensive background in financial leadership, capital markets, and strategic planning within the biotech sector is a significant addition, particularly as the company continues to advance its lead product, XOLREMDI, and manage its financial trajectory.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.6% of the 1872 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XFOR was trading at $4.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $385.3M. The 52-week trading range was $1.35 to $4.83. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.